Edition:
United States

Sophiris Bio Inc (SPHS.OQ)

SPHS.OQ on NASDAQ Stock Exchange Capital Market

3.75USD
22 Jun 2018
Change (% chg)

$-0.06 (-1.57%)
Prev Close
$3.81
Open
$3.83
Day's High
$3.83
Day's Low
$3.71
Volume
51,049
Avg. Vol
43,425
52-wk High
$4.04
52-wk Low
$1.80

Latest Key Developments (Source: Significant Developments)

Sophiris Bio Q4 Loss Per Share $0.13
Wednesday, 21 Mar 2018 04:05pm EDT 

March 21 (Reuters) - Sophiris Bio Inc ::SOPHIRIS BIO REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND KEY CORPORATE HIGHLIGHTS.Q4 LOSS PER SHARE $0.13.Q4 EARNINGS PER SHARE VIEW $-0.11 -- THOMSON REUTERS I/B/E/S.SOPHIRIS - EXPECTS CASH & CASH EQUIVALENTS WILL BE SUFFICIENT TO FUND OPERATIONS TO MIDDLE OF 2019, ASSUMING NO NEW CLINICAL TRIALS.  Full Article

Sophiris Bio posts Q3 loss per share $0.09
Thursday, 9 Nov 2017 04:05pm EST 

Nov 9 (Reuters) - Sophiris Bio Inc :Sophiris Bio reports third quarter financial results and key corporate highlights.Q3 loss per share $0.09.Q3 earnings per share view $-0.10 -- Thomson Reuters I/B/E/S.Sophiris Bio Inc - qtrly ‍total operating expenses $3.3 million versus $3.7 million.  Full Article

SOPHIRIS BIO ENTERED INTO LOAN AND SECURITY AGREEMENT OF UP TO $10 MLN IN TWO TERM LOANS​
Wednesday, 13 Sep 2017 04:05pm EDT 

Sept 13 (Reuters) - Sophiris Bio Inc :SOPHIRIS BIO- ‍ANNOUNCED THAT IT ENTERED INTO A LOAN AND SECURITY AGREEMENT WITH SILICON VALLEY BANK AND MAY BORROW UP TO $10 MILLION IN TWO TERM LOANS​.  Full Article

Sophiris Bio Q1 loss per share $0.09
Monday, 15 May 2017 04:05pm EDT 

May 15 (Reuters) - Sophiris Bio Inc :Sophiris Bio reports first quarter financial results and key corporate highlights.Q1 loss per share $0.09.Q1 earnings per share view $-0.09 -- Thomson Reuters I/B/E/S.Sophiris Bio - expects that its cash and cash equivalents will be sufficient to fund its operations through end of 2018.  Full Article

Sophiris Bio Q4 loss per share $0.02
Monday, 27 Mar 2017 09:00am EDT 

Sophiris Bio Inc : Sophiris Bio reports fourth quarter and full year 2016 financial results and key corporate highlights . Q4 loss per share $0.02 . Sophiris Bio Inc - at dec 31, 2016, co had cash, cash equivalents and securities available-for-sale of $29.0 million and working capital of $27.8 million . Sophiris Bio Inc - expects to receive six-month biopsy data for all patients in late 2017 or early 2018 . Sophiris Bio Inc - expects that its cash and cash equivalents will be sufficient to fund its operations through end of 2018 .Sophiris Bio- not planning on pursuing second phase 3 trial in bph,unless can secure development partner to fund new trial,obtain other financing.  Full Article

CVI Investments, Inc. reports 8.5 pct passive stake in Sophiris Bio
Friday, 26 Aug 2016 09:40am EDT 

: CVI Investments, Inc. reports 8.5 pct passive stake in Sophiris Bio as of August 23, 2016 - SEC Filing Source - http://bit.ly/2bSJTzU Further company coverage: [SPHS.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Sabby Management, LLC reports 8.53 pct passive stake in Sophiris Bio
Thursday, 25 Aug 2016 09:50am EDT 

Sophiris Bio Inc : Sabby Management, LLC reports 8.53 pct passive stake in Sophiris Bio as of August 23, 2016 - SEC Filing Source - http://bit.ly/2bkUhn5 Further company coverage: [SPHS.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Sophiris Bio currently evaluating options to further advance clinical development of Topsalysin
Monday, 22 Aug 2016 04:30pm EDT 

Sophiris Bio Inc : Currently evaluating options to further advance clinical development of topsalysin - sec filing . "will require significant additional funding to advance topsalysin in clinical development" . Could use dilutive funding options like equity financing or "non-dilutive" funding options to fund future clinical development of topsalysin . Do not plan on pursuing new clinical trials, including a second phase 3 trial in bph, unless we obtain additional financing .Believe that earliest we could commercialize topsalysin for treatment of localized prostate cancer would be in late 2021 or into 2022.  Full Article

Sophiris Bio announces proposed public offering of common shares
Monday, 22 Aug 2016 04:01pm EDT 

Sophiris Bio Inc :Sophiris Bio announces proposed public offering of common shares and warrants.  Full Article

Sophiris Bio Q2 loss per share $0.21
Tuesday, 9 Aug 2016 04:01pm EDT 

Sophiris Bio Inc : Q2 loss per share $0.21 .Sophiris bio reports second quarter 2016 financial results and key business highlights.  Full Article

BRIEF-Sophiris Bio Reports Q1 Loss Per Share $0.11

* SOPHIRIS BIO REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND KEY CORPORATE HIGHLIGHTS